On 25mg oral, four months in, and my results are closer to the low-dose injectable arm than to the numbers being quoted for 50mg.
The practical numbers: about 1% oral bioavailability, 30 minutes fasted before food, no more than 120ml of plain water, and coffee counts as food for this purpose.
The question I want answered is how much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly.
If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
This one has a reasonably settled answer, so here it is. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.
JessicaH_TX said:Orforglipron is the more interesting oral story because it is not a peptide at all.
No disagreement with JessicaH_TX. One condition attached. Worth adding that the tablet is taken daily, so a missed dose costs far less than a missed weekly injection. That is a genuine advantage nobody lists.
I would rather be corrected than agreed with, if it comes to it.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultsrachel_ABQ said:On 25mg oral, four months in, and my results are closer to the low-dose injectable arm than to the numbers being quoted for 50mg.
Same position here, arrived at the long way round. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.
From the other side of the consultation, briefly. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.